MBX smart money
Mbx Biosciences, INC. (MBX): 3 insider buys, 9 top funds holding it, 1 ETF change in the public filings.
Insider buys, 12 months$1.1M
Insider buys
| Filed | Who | Role | Amount | Price |
|---|---|---|---|---|
| 2026-03-16 | Hawryluk P. Kent | President & CEO | $526k | $28.41 |
| 2025-10-21 | Hawryluk P. Kent | President & CEO | $273k | $13.64 |
| 2025-10-20 | Hoerter Steven L. | Director | $265k | $13.25 |
Top 100 funds holding it
| # | Fund | Change | Weight | Value |
|---|---|---|---|---|
| 10 | Paradigm Biocapital Advisors LP | ADD +50% | 4.40% | $221M |
| 19 | Tcg Crossover Management, LLC | 1.08% | $38M | |
| 22 | Braidwell LP | TRIM -44% | 1.01% | $23M |
| 24 | Orbimed Advisors LLC | TRIM -10% | 3.33% | $180M |
| 30 | Deep Track Capital, LP | TRIM -63% | 0.63% | $38M |
| 31 | Affinity Asset Advisors, LLC | TRIM -33% | 0.17% | $3M |
| 60 | Kynam Capital Management, LP | 3.03% | $55M | |
| 76 | Polar Capital Holdings PLC | 0.26% | $94M | |
| 84 | Soleus Capital Management, L.P. | TRIM -50% | 0.54% | $15M |
ETF changes
| ETF | Change | Value | Report |
|---|---|---|---|
| State Street(R) Spdr(R) S&p(R) Pharmaceuticals ETF | ADD | +$600k | 2026-06-30 |